Sage Therapeutics, Inc. (SAGE) — Financial statements
Income statement, balance sheet, and cash flow for Sage Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 41↓52.3% | 86↑1024.8% | 8↑21.8% | 6↓99.4% | 1,114 | |
| Cost of Revenue | 9↑337.4% | 2↑165.6% | 0.81↑47.0% | 0.55↓2.1% | 0.57 | |
| Gross Profit | 32↓62.3% | 84↑1126.5% | 7↑19.4% | 6↓99.5% | 1,114 | |
| Operating Expenses | ||||||
| R&D Expenses | 226↓36.6% | 356↑9.2% | 326↑15.2% | 283↓3.3% | 293 | |
| General & Administrative Expenses | 216↓21.2% | 275↑20.6% | 228↑24.1% | 183↓6.8% | 197 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 216↓21.2% | 275↑20.6% | 228↑24.1% | 183↓6.8% | 197 | |
| Other Expenses | 22↓34.5% | 33↑222473.3% | 0.02↓88.8% | 0.13↓46.4% | 0.25 | |
| Operating Expenses | 464↓26.4% | 631↑13.9% | 554↑18.7% | 467↓4.7% | 490 | |
| Total Costs & Expenses | 474↓29.0% | 667↑20.2% | 555↑18.7% | 467↓4.7% | 490 | |
| Operating Results | ||||||
| Operating Income | -432↑25.4% | -580↓6.0% | -547↓18.7% | -461↓177.3% | 596 | |
| Depreciation & Amortization | 1↓26.0% | 1↑24.2% | 1↓73.2% | 4↑59.0% | 3 | |
| EBITDA | -409↑24.9% | -545↑0.1% | -546↓19.5% | -457↓172.9% | 627 | |
| EBIT | -411↑24.9% | -546↑0.1% | -547↓18.7% | -461↓173.9% | 624 | |
| Interest & Other Income | ||||||
| Net Interest Income | 32↓18.2% | 39↑173.0% | 14↑392.2% | 3↓70.0% | 10 | |
| Interest Income | 32↓18.2% | 39↑173.0% | 14↑392.2% | 3↓70.0% | 10 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -22↑34.5% | -33 | 0.00 | 0.00↑100.0% | -28 | |
| Other Income / Expenses | 32↓17.4% | 38↑170.0% | 14↑370.8% | 3↓69.4% | 10 | |
| Income Before Tax | -401↑26.0% | -541↓1.6% | -533↓16.4% | -458↓175.6% | 606 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -401↑26.0% | -541↓1.6% | -533↓16.4% | -458↓175.6% | 606 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -401↑26.0% | -541↓7.6% | -503↓11.6% | -451↓174.4% | 606 | |
| Bottom-Line Net Income | -401↑26.0% | -541↓1.6% | -533↓16.4% | -458↓175.6% | 606 | |
| EPS (Basic) | -6.59↑27.2% | -9.05↓6.6% | -8.49↓10.5% | -7.68↓165.9% | 11.66 | |
| EPS (Diluted) | -6.59↑27.2% | -9.05↓6.6% | -8.49↓10.5% | -7.68↓167.2% | 11.43 | |
| Weighted Average Shares | 61↑1.6% | 60↑0.9% | 59↑1.1% | 59↑12.9% | 52 | |
| Weighted Average Diluted Shares | 61↑1.6% | 60↑0.9% | 59↑1.1% | 59↑10.7% | 53 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.